February 2026 in “International Journal of Clinical Dermatology” A multi-drug treatment can effectively clear extensive calcinosis in juvenile dermatomyositis.
Infliximab was effective in treating a scalp condition that did not respond to other treatments.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
24 citations
,
March 2022 in “Journal of the American Academy of Dermatology” Adalimumab improved folliculitis decalvans in most patients.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
6 citations
,
August 2013 in “Joint Bone Spine” Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
60 citations
,
September 2013 in “Alimentary Pharmacology & Therapeutics” Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
19 citations
,
September 2006 in “Journal of Pediatric Gastroenterology and Nutrition” Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
80 citations
,
January 1995 in “The Nephron journals/Nephron journals” The treatment was effective for lupus nephritis with manageable side effects.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
3 citations
,
November 2021 in “Frontiers in medicine” Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.
8 citations
,
January 2013 in “European Journal of Dermatology” Alitretinoin may help treat alopecia areata.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
February 2016 in “Annals of the Rheumatic Diseases” All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
1 citations
,
November 1991 in “PubMed” Immunoadsorption successfully treated a man's resistant polymyositis.
1 citations
,
April 2025 in “Experimental Dermatology” Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
8 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology” 6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
9 citations
,
January 2013 in “Indian journal of dermatology, venereology, and leprology” Infliximab may cause hair loss in Crohn's disease patients.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.